Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Boston Scientific (BSX), Alto Neuroscience, Inc. (ANRO)

Tipranks - Tipranks - Thu Apr 16, 4:39AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Boston Scientific (BSX), Alto Neuroscience, Inc. (ANRO) and Demant (WILLF) with bullish sentiments.

Claim 30% Off TipRanks

Boston Scientific (BSX)

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Boston Scientific, with a price target of $100.00. The company’s shares closed last Tuesday at $63.82.

According to TipRanks.com, Jennings is a 2-star analyst with an average return of 0.0% and a 43.1% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Orchestra BioMed Holdings, and Baxter International. ;'>

Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $100.55, implying a 58.3% upside from current levels. In a report issued on April 2, Jefferies also maintained a Buy rating on the stock with a $110.00 price target.

See the top stocks recommended by analysts >>

Alto Neuroscience, Inc. (ANRO)

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Alto Neuroscience, Inc.. The company’s shares closed last Tuesday at $25.82.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 45.4% and a 54.7% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Praxis Precision Medicines, and Sionna Therapeutics, Inc. ;'>

Currently, the analyst consensus on Alto Neuroscience, Inc. is a Strong Buy with an average price target of $34.88, representing a 31.9% upside. In a report issued on April 1, Chardan Capital also maintained a Buy rating on the stock with a $30.00 price target.

Demant (WILLF)

In a report released today, Graham Doyle from UBS maintained a Buy rating on Demant, with a price target of DKK240.00. The company’s shares closed last Thursday at $29.64.

According to TipRanks.com, Doyle is a 1-star analyst with an average return of -2.3% and a 48.4% success rate. Doyle covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Siemens Healthineers AG, and Medacta Group SA. ;'>

Demant has an analyst consensus of Moderate Buy, with a price target consensus of $36.38, representing a 22.7% upside. In a report issued on April 13, Goldman Sachs also maintained a Buy rating on the stock with a DKK250.00 price target.

Read More on BSX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).